as 11-26-2024 4:00pm EST
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
Founded: | N/A | Country: | United States |
Employees: | N/A | City: | BOTHELL |
Market Cap: | 18.3M | IPO Year: | N/A |
Target Price: | $7.00 | AVG Volume (30 days): | 25.0K |
Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.84 | EPS Growth: | N/A |
52 Week Low/High: | $1.33 - $3.10 | Next Earning Date: | 11-13-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
COCP Breaking Stock News: Dive into COCP Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
7 days ago
Simply Wall St.
12 days ago
GlobeNewswire
13 days ago
GlobeNewswire
a month ago
Simply Wall St.
a month ago
GlobeNewswire
2 months ago
GlobeNewswire
3 months ago
Zacks Small Cap Research
3 months ago
The information presented on this page, "COCP Cocrystal Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.